Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Embolism: later-stage trial registry
13 of 49 indexed Pulmonary Embolism trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #281 of 28,707 conditions by registered trial count.
49 US clinical trials · 13 currently recruiting · #281 of 28,707 conditions by registered trial count
Pulmonary Embolism: 49 US clinical trials tracked, 13 recruiting.
Pulmonary Embolism is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 5 of these trials.
Enrollment posture brief
Registry condition pulmonary-embolism
OPEN 13 | RECR 27% | LATE 9 | EARLY 5 | RANK #281 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Hepatic Impairment (27% recruiting · 49 trials)
Pulmonary Embolism lists 13 open slots (27% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Embolism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Embolism is recruiting below its size-band peers.
13 of 49 indexed trials (26.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pulmonary Embolism trials is spread across many organizations.
Brigham and Women's Hospital accounts for 5 of 49 trials (10.2%). 41 distinct sponsors appear on at least one study for this condition label.
-
Typical Pulmonary Embolism enrolment sits around 200 participants.
Median target enrolment is 200 among the 49 trials that report a genuine target (sentinel values excluded). 12 of those (24.5%) plan for fewer than 100 participants.
-
Pulmonary Embolism splits between interventional and observational designs.
33 interventional and 16 observational studies make up this index (67.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
49 total, page 1 of 1
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Penumbra
NCT04798261
The PEERLESS II Study
Inari Medical
NCT06055920
Aspiration Thrombectomy Using the Symphony or Prodigy System
Imperative Care
NCT07350499
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NYU Langone Health
NCT05591118
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
WellSpan Health
NCT05050617
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
Brigham and Women's Hospital
NCT06538376
The PERSEVERE Study
Inari Medical
NCT06588634
Endovascular Engineering ENGULF Study
Endovascular Engineering
NCT05597891
CLEANer Aspiration for Pulmonary Embolism
Argon Medical Devices
NCT06189313
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
Innova Vascular
NCT06041594
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
Mayo Clinic
NCT06695247
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
Massachusetts General Hospital
NCT05891886
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
Medical University of South Carolina
NCT06451003
US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
Adient Medical
NCT05127915
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
Boston Scientific Corporation
NCT04790370
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Anthos Therapeutics
NCT05171075
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
University of Michigan
NCT05351749
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
Inova Health Care Services
NCT07250763
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Inquis Medical
NCT05907564
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II
Jupiter Endovascular
NCT06576427
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
University of Texas Southwestern Medical Center
NCT04583878
Comparing Electrical Impedance Tomography to Computed Tomographic Angiography
Colorado State University
NCT05546333
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
Northwell Health
NCT03581877
Michigan Emergency Department Improvement Collaborative (MEDIC) Alert; Pulmonary Embolism (PE)
University of Michigan
NCT06312332
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT04879407
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events
Vanderbilt University Medical Center
NCT04574895
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
Thrombosis Research Institute
NCT02155491
Epidemiology of Venous Thromboembolism
Brigham and Women's Hospital
NCT00456196
Prospective Investigation of Pulmonary Embolism Diagnosis III
George Washington University
NCT00241826
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT01828697
Short-term Clinical Deterioration After Acute Pulmonary Embolism
Wake Forest University Health Sciences
NCT03915925
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
McMaster University
NCT00720915
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
Brigham and Women's Hospital
NCT00401414
Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT
Stanford University
NCT01097928
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
NCT02585713
Evaluation of Obstructive Sleep Apnea as a Risk Factor for Pulmonary Embolism
Atlantic Health System
NCT00409045
Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
Abbott RDx Cardiometabolic
NCT01037270
Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population
Memorial Sloan Kettering Cancer Center
NCT00615147
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
University of Puerto Ri
NCT02345356
Identify Clinical Conditions That Increase Circulating DNA Levels
University of Florida
NCT01815996
Detection of Pulmonary Embolism With CECT
Bracco Diagnostics
NCT00351754
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Thrombolex
NCT04248868
Nitric Oxide to Treat Pulmonary Embolism
Indiana University School of Medicine
NCT01939301
Non-Interruptive Alerts for Improving Use of Clinical Decision Rules
University of Utah
NCT04702308
Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
Brigham and Women's Hospital
NCT00413374
Home Rehabilitation After Acute Pulmonary Embolism
University of Rochester
NCT05571189
Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism
Wake Forest University Health Sciences
NCT00848731
Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
University of Pittsburgh
NCT00436787
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Thrombolex
NCT03927508
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Embolism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Embolism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Embolism page
49 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Pulmonary Embolism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brigham and Women's Hospital sponsors the most Pulmonary Embolism trials on record, review their full trial history before evaluating a specific study. See Brigham and Women's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Embolism condition card totals 49 registered trials; most-linked intervention The Bashir™ Endovascular Catheter; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.